MDR focus Target a collaboration that leverages Hsiri Therapeutics’ focus on developing novel antibiotics for multi-drug resistant Gram-negative and mycobacterial infections, presenting opportunities to co-develop or license new antimicrobial programs.

Strategic partner Explore licensing or research partnership with larger pharmaceutical companies seeking to expand their infectious disease portfolios, leveraging Hsiri’s niche in NTM, TB, and non-tuberculous mycobacterial diseases.

Early-stage collaboration Position as a partner for early-stage discovery and preclinical collaboration to advance novel antibiotic candidates, offering access to specialized programs while de-risking scale-up for potential sponsors.

Development funding Propose milestone-driven funding and co-development models to align with Hsiri’s current revenue profile and private status, highlighting potential for shared risk in antibiotic R&D.

Market positioning Highlight the unmet need in MDR Gram-negative and mycobacterial infections to attract investors and strategic buyers looking to strengthen anti-infective pipelines, with emphasis on competing in a high-need, high-value segment.